Lutetium-177 (177Lu) was chosen for the therapeutic Miltuximab® conjugate, given its promising clinical application when used with prostate-specific membrane antigen (PSMA) therapy in PCa [18]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.